Placebo 6mg tablets
Sponsors
Sanofi-Aventis Recherche & Developpement
Conditions
Fabry DiseaseGaucher's disease type III
Phase 3
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age with Fabry Disease who are treatment-naïve or Untreated for at Least 6 Months
Active, not recruitingCTIS2024-511990-31-00
Start: 2022-06-28Target: 48Updated: 2025-11-14
LEAP2MONO - EFC17215 A phase 3, multicenter, multinational, randomized, double-blind, double-dummy, active-comparator study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 3 (GD3) who have reached therapeutic goals with Enzyme Replacement Therapy (ERT)
Active, not recruitingCTIS2024-514381-39-00
Start: 2022-12-08Target: 15Updated: 2025-11-14